Circassia

Contact
circassia.co.uk
+441865784574

Circassia Holding Ltd.

Magdalen Centre, The Oxford Science Park
OX4 4GA Oxford
United Kingdom
+441865784574
circassia.co.uk
Contact
Profile Products News
Contact

About Circassia

Circassia is a specialty biopharmaceutical company focused on developing medicines designed to control immune system responses. The company has a highly experienced management team with a proven track record in product development and commercialization, and having successfully completed two substantial fundraising rounds is backed by a syndicate of world-class venture capital and institutional investors, which includes Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

Read more about Circassia
Facts about Circassia
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of Circassia

Product portfolio

Show all

News about Circassia

Circassia

26-Feb-2013 | research and development

Circassia’s cat allergy treatment shows sustained symptom improvement

Imperial Innovations Group plc announced that portfolio company Circassia has seen strong results from its follow up phase II clinical trial. Patients saw ...

Read news
Circassia

09-Oct-2012 | research and development

Circassia initiates phase III trial for cat allergy treatment

Imperial Innovations Group plc announced that its portfolio company, Circassia has initiated a pivotal large-scale phase III clinical study of its ...

Read news
Circassia

09-Mar-2012 | research and development

Circassia ragweed vaccine achieves phase II clinical development milestone

Imperial Innovations Group plc announces that portfolio company Circassia has successfully completed a large-scale phase II clinical study of its ...

Read news
Circassia

04-Oct-2010 | research and development

Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies

Circassia also advances Phase III Plans for cat Allergy T-Cell Vaccine

Read news
Circassia

21-Jan-2010 | research and development

Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies

Circassia Ltd announced that it has initiated phase II clinical trials of its T-cell vaccines targeting house dust mite and cat allergies. With the start ...

Read news
Circassia

15-Sep-2008 | research and development

Circassia Achieves Successful Phase II Clinical Results With ToleroMune Anti-Allergy Technology

Circassia Ltd announced positive results from a phase II clinical study of its anti-allergy technology, ToleroMune(R), in the field of cat allergy. The ...

Read news
Circassia

28-Feb-2008 | research and development

Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology

Circassia Ltd announced that it has initiated a phase II clinical study with its anti-allergy technology, ToleroMune. Circassia is conducting the study in ...

Read news
Circassia

06-Jul-2007 | people

Circassia Appoints Sir Richard Sykes as Chairman of the Board

Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, announced the appointment of Sir Richard Sykes as ...

Read news
Show more news about Circassia

Here you will find Circassia Holding Ltd.